share_log
Benzinga ·  Apr 25 07:25
Purple Biotech Says Randomized Phase 2 CM24 Pancreatic Cancer Study Selected As Late-Breaking Abstract Poster Presentation At ASCO 2024 Annual Meeting
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment